AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMURON LTD

0.033

0.000

Volume:- -

Turnover:- -

Market Cap:10.78M

PE:-1.43

High:0.033

Open:0.033

Low:0.033

Close:0.033

52wk High:0.098

52wk Low:0.026

Shares:326.65M

Float Shares:265.37M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.023

ROE:-39.68%

ROA:-21.93%

PB:0.82

PE(LYR):-1.46

Loading ...

Overview Company News Filings

Immuron Limited Issues 1.13 Million New Shares in Placement

Immuron CEO to Present at Emerging Growth Conference

Emerging Growth Research Initiates Coverage on Immuron Limited with Buy-Extended Rating, Sets $4.00 Price Target

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

BRIEF-Immuron Q1 Fy26 YoY Growth

Immuron Limited Reports 34% Global Sales Growth in Q1 FY26, Driven by Strong Performance in Australia and USA

Immuron Q1 FY26 YoY Growth

THOMSON REUTERS

Immuron Says Fiscal Q1 Global Sales of Over-the-Counter Immune Supplement Up 34% Year-over-Year, Shares Fall 6%

MT Newswires Live

BRIEF-Immuron Posts Q1 FY26 Global Sales AUD$2.0 Million

Immuron Ltd - Q1 FY26 Global Sales AUD$2.0 Mln

THOMSON REUTERS

Pegatron 5G Accelerates Make in India with Innovative 5G Small Cell and Smart Manufacturing at IMC 2025

Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026

THOMSON REUTERS

Immuron Submits Imm-529 Ind to FDA

THOMSON REUTERS

Immuron Submits Investigational New Drug Application for Clostridioides Difficile Infection Treatment Candidate to the US FDA

MT Newswires Live

Immuron Extends At-the-Market Funding Facility to Aggregate Offering Price of Around $2.8 Million

MT Newswires Live

Immuron Limited Announces Increase of At-the-Market Offering Program by $2.85 Million

Shares of Immuron Rise as Reports No Impact From US Tariffs

MT Newswires Live

Immuron Limited Publishes Shareholder Letter Covering Fiscal Year Ending June 30, 2025

Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials

Immuron Letter to Shareholders – Projects Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMC.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.033,"timestamp":1774588320000,"preClose":0.033,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":326653609,"eps":-0.023,"marketStatus":"Market Closed","change":0,"latestTime":"03-27 16:12:00 AEDT","open":0.033,"high":0.033,"low":0.033,"amount":0,"amplitude":0,"askPrice":0.032,"askSize":300000,"bidPrice":0.029,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.023,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.033,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMC.AU","preClose":0.03,"auctionPrice":0.03,"auctionVolume":4424,"auction":3,"marketStatus":"盘后竞价","timestamp":1774501204664}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-21.93%","roe":"-39.68%","lyrEps":-0.022586,"shares":326653609,"dividePrice":0,"high":0.033,"amplitude":0,"preClose":0.033,"low":0.033,"week52Low":0.026,"pbRate":"0.82","psRate":"1.44","week52High":0.098,"institutionHeld":0,"latestPrice":0.033,"committee":-0.714286,"eps":-0.023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.023,"open":0.033,"prevYearClose":0.036,"prevWeekClose":0.027,"prevMonthClose":0.028,"prevQuarterClose":0.036,"fiveDayClose":0.027,"twentyDayClose":0.028,"sixtyDayClose":0.036},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577825947","title":"Immuron Limited Issues 1.13 Million New Shares in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577825947","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577825947?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:02","pubTimestamp":1761040971,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced the issuance of 1,133,840 new ordinary fully paid shares through a placement previously disclosed to the market. The new shares will be quoted on the ASX under the code IMC. This issuance follows the proposed issue of securities outlined in an earlier Appendix 3B announcement. No further issues of securities are expected to complete this transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL5yLMw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2576853672","title":"Immuron CEO to Present at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2576853672","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576853672?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:58","pubTimestamp":1760957935,"startTime":"0","endTime":"0","summary":"Immuron Limited announced that its Chief Executive Officer, Steven Lydeamore, will present virtually at the Emerging Growth Conference on Wednesday, October 22, 2025. Lydeamore will deliver a presentation and may open the floor for questions from attendees.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL4Pfn4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2576054320","title":"Emerging Growth Research Initiates Coverage on Immuron Limited with Buy-Extended Rating, Sets $4.00 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2576054320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576054320?lang=en_us&edition=fundamental","pubTime":"2025-10-17 23:08","pubTimestamp":1760713685,"startTime":"0","endTime":"0","summary":"Emerging Growth Research has initiated coverage on Immuron Limited  with a Buy-Extended rating and set a 12-month price target of $4.00, representing over 80% upside from its recent closing price. The report highlights Immuron's strong revenue growth from its over-the-counter product Travelan, an expanding clinical pipeline targeting major infectious diseases, and strategic partnerships with organizations such as the U.S. Department of Defense and Monash University. Immuron's innovative polyclonal antibody platform and robust global market potential, along with a strong balance sheet and upcoming clinical milestones, position the company for significant long-term value, according to the research firm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL7SJXwy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2576956774","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2576956774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576956774?lang=en_us&edition=fundamental","pubTime":"2025-10-17 07:07","pubTimestamp":1760656037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUE7FFTV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2575477317","title":"BRIEF-Immuron Q1 Fy26 YoY Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2575477317","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575477317?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:28","pubTimestamp":1760351327,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Q1 Fy26 YoY GrowthOct 13 (Reuters) - Immuron Ltd IMC.AX:IMMURON Q1 FY26 YOY GROWTHSource text: ID:nGNXbhgPM1Further company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA1NPCZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2575474714","title":"Immuron Limited Reports 34% Global Sales Growth in Q1 FY26, Driven by Strong Performance in Australia and USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2575474714","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575474714?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:00","pubTimestamp":1760349618,"startTime":"0","endTime":"0","summary":"Immuron Limited has reported unaudited Q1 FY26 sales results, highlighting significant global growth for its Travelan product. Global Q1 sales reached AUD$2.0 million, up 34% on the prior comparative period . In Australia, sales climbed 52% to AUD$1.6 million, attributed to increased brand awareness, digital and social media marketing, and new store listings. The U.S. market saw Q1 sales rise 44% to AUD$0.4 million, driven by enhancements to the Travelan Amazon store and expanded social media marketing efforts. Conversely, Canadian Q1 sales dropped 92% to AUD$0.0 million, reflecting the typical seasonal lull following a pipeline fill into over a thousand retail doors in the previous year. The company expects sales in Canada to pick up later in the year with increased consumer promotions and brand awareness campaigns.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDLcdlrLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK7508","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","BK4588","IMC.AU","IE00B3QW5Z07.USD","NDAQ","BK7067","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2575047419","title":"Immuron Q1 FY26 YoY Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2575047419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575047419?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:00","pubTimestamp":1760349600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA1NPCZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2575421341","title":"Immuron Says Fiscal Q1 Global Sales of Over-the-Counter Immune Supplement Up 34% Year-over-Year, Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575421341","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575421341?lang=en_us&edition=fundamental","pubTime":"2025-10-13 13:29","pubTimestamp":1760333384,"startTime":"0","endTime":"0","summary":"Immuron  reported sales of AU$1.6 million for its over-the-counter immune supplement Travelan in Australia for the fiscal first quarter was up 52% year-over-year, and sales of AU$2 million globally, increasing 34% from the prior corresponding period, according to a Monday Australian bourse filing.The continued growth in Australia can be attributed to \"increased awareness and consideration\" driven by marketing, as well as same-store growth as a result of market promotions.Its shares fell 6% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XKO.AU","IMC.AU","BK7067","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2575418954","title":"BRIEF-Immuron Posts Q1 FY26 Global Sales AUD$2.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2575418954","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575418954?lang=en_us&edition=fundamental","pubTime":"2025-10-13 08:33","pubTimestamp":1760315620,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Posts Q1 FY26 Global Sales AUD$2.0 MillionOct 13 (Reuters) - Immuron Ltd IMC.AX:Q1 FY26 GLOBAL SALES AUD$2.0 MILLIONFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VR1RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2575443936","title":"Immuron Ltd - Q1 FY26 Global Sales AUD$2.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2575443936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575443936?lang=en_us&edition=fundamental","pubTime":"2025-10-13 06:21","pubTimestamp":1760307686,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251012:nFWN3VR1RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2573923391","title":"Pegatron 5G Accelerates Make in India with Innovative 5G Small Cell and Smart Manufacturing at IMC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923391","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923391?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:11","pubTimestamp":1759925460,"startTime":"0","endTime":"0","summary":"NEW DELHI, Oct. 8, 2025 /PRNewswire/ -- Pegatron 5G, a new business unit of Pegatron, a globally leading manufacturing company announces its participation at the India Mobile Congress  2025, the nation's largest digital technology event with the theme \"Innovation: The Engine of India's Progress\", Pegatron 5G will play the role of supplying advanced 5G technology in accelerating transformation across industries thus paving the way for Viksit Bharat 2047.Pegatron 5G showcase its 5G Radio portfolio at IMC 2025. RedCap:the integration of PG5200, Muscat, MD200, PR1450, and PS1400 - designed to provide a cost-effective and power-efficient way to connect industrial and IoT devices to 5G networks. RedCap devices are simpler, with reduced RF chain complexity and lower bandwidth requirements. For network operators or enterprise/private networks, simpler devices and reduced throughput demands can reduce infrastructure and ongoing operational costs.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2791423/20251008_073123728_iOS.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2791423/20251008_073123728_iOS.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pegatron-5g-accelerates-make-in-india-with-innovative-5g-small-cell-and-smart-manufacturing-at-imc-2025-302578310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNDmain","BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2573448719","title":"Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573448719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573448719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:00","pubTimestamp":1759917600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA3Y2GPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2573443849","title":"Immuron Submits Imm-529 Ind to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2573443849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573443849?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:00","pubTimestamp":1759917600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA3Y2GPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2573912270","title":"Immuron Submits Investigational New Drug Application for Clostridioides Difficile Infection Treatment Candidate to the US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2573912270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573912270?lang=en_us&edition=fundamental","pubTime":"2025-10-08 14:02","pubTimestamp":1759903360,"startTime":"0","endTime":"0","summary":"Immuron  submitted an investigational new drug application to the US Food and Drug Administration  for the clinical development of IMM-529 to treat Clostridioides difficile infection and prevent recurrent infection, according to a Wednesday Australian bourse filing.It plans to initiate a second-phase clinical trial for the treatment candidate in individuals with Clostridioides difficile infection during the first half of 2026. The clinical trial is expected to enroll both first-episode and recurrent infection patients.The firm's shares rose over 1% in recent trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2573621008","title":"Immuron Extends At-the-Market Funding Facility to Aggregate Offering Price of Around $2.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2573621008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573621008?lang=en_us&edition=fundamental","pubTime":"2025-10-06 14:29","pubTimestamp":1759732150,"startTime":"0","endTime":"0","summary":"Immuron  lodged an at-the-market supplementary prospectus with the United States Securities and Exchange Commission, extending the at-the-market funding facility with H.C. Wainwright to an additional aggregate offering price of around $2.8 million, according to a Monday Australian bourse filing.Immuron will control major aspects of the funding, having sole discretion as to whether the firm uses the at-the-market facility, the number of American depository shares issued, as well as the minimum issue price of the American depository shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2572838176","title":"Immuron Limited Announces Increase of At-the-Market Offering Program by $2.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2572838176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572838176?lang=en_us&edition=fundamental","pubTime":"2025-10-03 21:57","pubTimestamp":1759499865,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced an increase to its at-the-market  offering program with H.C. Wainwright & Co., LLC, allowing the company to offer and sell additional American Depositary Shares  representing its ordinary shares. The maximum aggregate offering price under the ATM Agreement has been increased by approximately $2.85 million. The ADSs will be issued and sold from time to time at Immuron's discretion, with proceeds intended to support the company's ongoing operations and growth initiatives. Sales will be conducted pursuant to the company's effective shelf registration statement on Form F-3 and related prospectus.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL9T2DBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2572576704","title":"Shares of Immuron Rise as Reports No Impact From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2572576704","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572576704?lang=en_us&edition=fundamental","pubTime":"2025-10-03 12:35","pubTimestamp":1759466135,"startTime":"0","endTime":"0","summary":"Shares of Immuron  rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration  phase 3 trials.In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2572515985","title":"Immuron Limited Publishes Shareholder Letter Covering Fiscal Year Ending June 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572515985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572515985?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:06","pubTimestamp":1759399610,"startTime":"0","endTime":"0","summary":"Immuron Limited has released a shareholder letter outlining several updates. The company does not expect any material impact from recent US tariffs on pharmaceutical products. Topline results from the Travelan clinical study conducted by Uniformed Services University are anticipated in October 2025. An Investigational New Drug  application for IMM-529, targeting Clostridioides difficile infection, is planned for submission to the U.S. FDA in mid-October 2025. The Australian commercial launch of ProIBS is scheduled for the fourth quarter of 2025, with a full launch expected in the first quarter of 2026. Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci, are expected to be completed by the end of 2025. The full letter can be accessed through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL3GsVPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2572251530","title":"Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2572251530","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572251530?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:00","pubTimestamp":1759399214,"startTime":"0","endTime":"0","summary":"Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL7q19xD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","IMC.AU","LU2095319765.USD","BK4112","LU0314104364.USD","BK7508","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK7067","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2572515354","title":"Immuron Letter to Shareholders – Projects Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2572515354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572515354?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:00","pubTimestamp":1759399200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nTUA2ZXSS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}